The ethanolic (v/v) Cimicifuga racemosa
dry extract Ze 450 was manufactured of dried rhizomes and roots and obtained from Max Zeller Soehne AG (Romanshorn, Switzerland).
In a previous study, the efficacy and tolerability of a standardised isopropanolic extract of the rootstock of Cimicifuga racemosa
(iCR) (Remifemin, manufactured by Schaper & Bruemmer) was compared to tibolone (produced by Zizhu Pharm), a Selective Oestrogen Receptor Modulator (SERM) that has agonistic and/ or antagonist effect on oestrogen, progesterone and androgen receptors, in Chinese women aged 40-60 years with menopausal symptoms, in a randomised, double-blind, placebo-controlled study.
Osteoprotective effects of Cimicifuga racemosa
and its triterpene-saponins are responsible for reduction of bone marrow fat.
(CR) extracts are described in a monograph of the European Scientific Cooperative on Phytotherapy (ESCOP) as pharmacologically active treatment of climacteric symptoms (ESCOP 2003) and in the community herbal monograph of the Committee on Herbal Medicinal Products of the European Medicines Agency (EMA 2010) its well-established use status was granted.
Remifemin[R], an extract of Cimicifuga racemosa
has been used in Germany for the relief of menopausal symptoms since the mid 1950s (Jellin 1999).
We previously observed that an extract of Cimicifuga racemosa
(CR) BNO 1055 was able to reduce ovariectomy induced obesity and this was associated with reduced loss of bone mineral density (BMD) as determined by quantitative computer tomography (qCT) (Seidlova-Wuttke et al.
As plant material the special extract from Cimicifuga racemosa
CR BNO 1055 (Bionorica SE, Neumarkt, Germany) was used, of which the preparation was described previously (kapur et al.
(Black Cohosh) This herb is well known in botanical medicine as a woman's herb.
Extracts from the medicinal plant Cimicifuga racemosa
(CR) have also been shown in several studies to reduce climacteric complaints, in others they were ineffective (Wuttke et al.
The paper, entitled "Critical Evaluation of the Safety of Cimicifuga Racemosa
in Menopause Symptom Relief," is the first to review all published literature pertaining to pre-clinical and clinical safety of various forms of Cimicifuga, as well as the FDA and World Health Organization adverse event reporting systems, monographs, compendia, internal unpublished data from a major manufacturer, foreign literature, and historical, anecdotal reports.
Studies on the endocrine effects of the contents of Cimicifuga racemosa
(black cohosh) is a herbaccous perennial plant, that has been traditionally used for a variety of ailments (dyspepsia, climacteric complaints, muscular rheumatisms, menstrual cramps).